A Study to Evaluate the Impact of Clacoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients - Trial NCT06415292
Access comprehensive clinical trial information for NCT06415292 through Pure Global AI's free database. This Phase 4 trial is sponsored by Sun Pharmaceutical Industries Limited and is currently Completed. The study focuses on Acne Vulgaris. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sun Pharmaceutical Industries Limited
Timeline & Enrollment
Phase 4
Nov 27, 2023
Dec 16, 2023
Primary Outcome
The primary endpoint is the change in corneometry reading between the two sides of the face treated with Winlevi versus no treatment.
Summary
Acne medications are a common source of facial dryness resulting in skin barrier damage and
 poor patient compliance. Retinoids and benzoyl peroxide are some of the most frequently
 prescribed and effective acne medications, however, dryness is an unwanted side effect. A new
 acne medication, 1% clascoterone, has been placed in a novel vehicle for excellent drug
 delivery in combination with excellent barrier properties. The barrier properties of 1%
 clascoterone have never been demonstrated. This study is aimed at better understanding the
 positive barrier effects of 1% clascoterone.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06415292
Non-Device Trial